[1]Kalakonda N., Maerevoet M., Cavallo F. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL) : a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7:e511-e522. 7
[2]The National Comprehensive Cancer Network diffus large B-cell lymphoma. 2017. https://www.nccn.org/patients/guidelines/content/PDF/nhl-diffuse-patient.pdf.
[3]Sehn L.H., Herrera A.F., Flowers C.R. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38:155-165. 2